FDA EIR - Aliri USA Inc. - February 12, 2009

An FDA Establishment Inspection was conducted at Pyxant Labs, Inc., located in Colorado Springs, CO, spanning from February 2, 2009, to February 12, 2009. This multi-day assessment involved a team of FDA investigators and chemists, focused on evaluating the firm's adherence to federal regulatory requirements pertinent to its laboratory operations. At the conclusion of the inspection, an FDA-483, documenting Inspectional Observations, was issued to Maurice A. Gaubatz, the President and CEO. This document highlighted several objectionable conditions identified within the firm's processes and facilities, which are critical for maintaining quality and compliance under the FDA's regulatory framework. Although the specific details of these violations are not provided in this excerpt, their enumeration on the FDA-483 indicates areas where the firm did not meet established guidelines. In response, Pyxant Labs, Inc. formally agreed to rectify all noted objectionable conditions. The company committed to submitting a comprehensive written response within two weeks, detailing the corrective actions undertaken to resolve these issues and ensure future compliance. No samples were collected, and the firm cooperated fully without any refusals during the inspection.